Logo

Enigma Biomedical - USA Partners with Alamar Biosciences to Advance the Diagnostics for Neurodegenerative Diseases

Share this
Enigma Biomedical

Enigma Biomedical - USA Partners with Alamar Biosciences to Advance the Diagnostics for Neurodegenerative Diseases

Shots:

  • Enigma Biomedical USA and Alamar Biosciences have partnered under which EB gains non-exclusive rights to introduce Alamar's ARGO HT instrument and NULISA reagent kits to academic and pharma customers in neurology research
  • The partnership aims to generate a large data set from neuroimaging & immunoassays, leading to more effective diagnostic solutions for patient-specific therapies
  • Enigma Biointelligence (EBI), an affiliate of EB, will allow users to order Alamar’s immunoassays via EBI’s Minerva Bio Platform. EBI’s Health Grid will help academic and pharma sponsors manage and interpret study data, incl. data from EB’s PET tracers and NULISA tests. EB and Alamar plan to develop analytics products from shared customer data

Ref: Businesswire | Image: Enigma Biomedical & Alamar Biosciences

Related News:- AbbVie and Enigma Biomedical Group (EBG-USA) Enter into a Licensing Agreement to Develop and Commercialize 4R Tau PET Imaging Biomarkers

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions